Literature DB >> 19557827

Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models.

Sandra Pereson1, Hans Wils, Gernot Kleinberger, Eileen McGowan, Mado Vandewoestyne, Bianca Van Broeck, Geert Joris, Ivy Cuijt, Dieter Deforce, Michael Hutton, Christine Van Broeckhoven, Samir Kumar-Singh.   

Abstract

Amyloid-beta (Abeta) plaques are pathological hallmarks of Alzheimer disease (AD). In addition, innate inflammatory responses, such as those mediated by microglia, are integral to the pathogenesis of AD. Interestingly, only dense-core plaques and not diffuse plaques are associated with neuritic and inflammatory pathology in AD patients as well as in mouse AD models. However, the precise neuropathological changes that occur in the brain in response to amyloid deposition are largely unknown. To study the molecular mechanism(s) responsible for Abeta-mediated neuropathology, we performed a gene expression analysis on laser-microdissected brain tissue of Tg2576 and APPPS1 mice that are characterized by different types of amyloid plaques and genetic backgrounds. Data were validated by image and biochemical analyses on different ages of Tg2576, APPPS1, and Abeta42-depositing BRI-Abeta42 mice. Consistent with an important role of inflammatory responses in AD, we identified progranulin (mouse Grn; human GRN) as one of the top ten up-regulated molecules in Tg2576 ( approximately 8-fold increased) and APPPS1 ( approximately 2-fold increased) mice compared to littermate controls, and among the eight significantly up-regulated molecules common to both mouse models. In addition, Grn levels correlated significantly with amyloid load, especially the dense-core plaque pathology (p < 0.001). We further showed that Grn is up-regulated in microglia and neurons and neurites around dense-core plaques, but not in astrocytes or oligodendrocytes, as has been shown in AD patients. Our data therefore support the ongoing use of these mouse models in drug trials, especially those with anti-inflammatory compounds. Moreover, the correlation of Grn with increasing disease severity in AD mouse models prompts human studies exploring the viability of GRN as a disease biomarker. Because loss of GRN has recently been shown to cause frontotemporal dementia and serves as a risk factor for AD, the strong GRN reactivity around dense-core plaques is consistent with an important role of this factor in AD pathogenesis. 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557827     DOI: 10.1002/path.2580

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  44 in total

1.  Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice.

Authors:  Fangfang Yin; Rebecca Banerjee; Bobby Thomas; Ping Zhou; Liping Qian; Ting Jia; Xiaojing Ma; Yao Ma; Costantino Iadecola; M Flint Beal; Carl Nathan; Aihao Ding
Journal:  J Exp Med       Date:  2009-12-21       Impact factor: 14.307

2.  Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques.

Authors:  Swetha Gowrishankar; Peng Yuan; Yumei Wu; Matthew Schrag; Summer Paradise; Jaime Grutzendler; Pietro De Camilli; Shawn M Ferguson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

3.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Authors:  Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter
Journal:  Acta Neuropathol       Date:  2017-01-09       Impact factor: 17.088

4.  Genetic Regulation of Neuronal Progranulin Reveals a Critical Role for the Autophagy-Lysosome Pathway.

Authors:  Lisa P Elia; Amanda R Mason; Amela Alijagic; Steven Finkbeiner
Journal:  J Neurosci       Date:  2019-01-29       Impact factor: 6.167

5.  Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging.

Authors:  Zeshan Ahmed; Hong Sheng; Ya-Fei Xu; Wen-Lang Lin; Amy E Innes; Jennifer Gass; Xin Yu; Charles A Wuertzer; Harold Hou; Shuichi Chiba; Keitaro Yamanouchi; Malcolm Leissring; Leonard Petrucelli; Masugi Nishihara; Michael L Hutton; Eileen McGowan; Dennis W Dickson; Jada Lewis
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

6.  miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease.

Authors:  Wang-Xia Wang; Bernard R Wilfred; Sindhu K Madathil; Guiliang Tang; Yanling Hu; James Dimayuga; Arnold J Stromberg; Qingwei Huang; Kathryn E Saatman; Peter T Nelson
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

7.  Understanding the role of progranulin in Alzheimer's disease.

Authors:  Simon D'Alton; Jada Lewis
Journal:  Nat Med       Date:  2014-10       Impact factor: 53.440

8.  Progranulin is a chemoattractant for microglia and stimulates their endocytic activity.

Authors:  Fiona Pickford; Jacob Marcus; Luiz Miguel Camargo; Qiurong Xiao; Danielle Graham; Jan-Rung Mo; Matthew Burkhardt; Vinayak Kulkarni; Jamie Crispino; Heike Hering; Michael Hutton
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

9.  Progranulin expression is upregulated after spinal contusion in mice.

Authors:  Swati B Naphade; Kristina A Kigerl; Lyn B Jakeman; Sandra K Kostyk; Phillip G Popovich; Jeff Kuret
Journal:  Acta Neuropathol       Date:  2009-11-28       Impact factor: 17.088

Review 10.  The Role of PGRN in Alzheimer's Disease.

Authors:  Hua Jing; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2015-07-28       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.